Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy
Marina Baretti, Mark Yarchoan
Marina Baretti, Mark Yarchoan
Published August 16, 2021
Citation Information: J Clin Invest. 2021;131(16):e151002. https://doi.org/10.1172/JCI151002.
View: Text | PDF
Commentary Article has an altmetric score of 4

Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy

  • Text
  • PDF
Abstract

Immune-checkpoint inhibitors are firmly established as pillars of cancer therapy, but only a minority of cancer patients currently benefit from these therapies, and therapeutic combinations that can enhance responses are urgently needed. Recently, histone deacetylases (HDACs) have emerged as potential targets for immune modulation, but critical questions remain about their mechanisms of action. In this issue of the JCI, Truong et al. assess whether the HDAC inhibitor entinostat can enhance anti–PD-1 treatment in a bladder cancer model. Entinostat promoted a T cell–inflamed phenotype and had substantial antitumor efficacy when used in combination with anti–PD-1 therapy. In addition, the authors showed that HDAC inhibition augmented tumor neoantigen presentation, resulting in the immune editing of tumor antigens. This study highlights a mechanism by which epigenetic modifier agents can synergize with immune-checkpoint blockade for enhanced and long-lasting antitumor activity.

Authors

Marina Baretti, Mark Yarchoan

×

Total citations by year

Year: 2025 2024 2023 2022 Total
Citations: 1 2 1 7 11
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2022 (7)

Title and authors Publication Year
DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway
Ding S, Gao Y, Lv D, Tao Y, Liu S, Chen C, Huang Z, Zheng S, Hu Y, Chow LK, Wei Y, Feng P, Dai W, Wang X, Xia Y
EBioMedicine 2022
Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma
Lu X, Liu M, Yang J, Que Y, Zhang X
Clinical & Experimental Immunology 2022
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.
Kandalaft LE, Dangaj Laniti D, Coukos G
Nature reviews. Cancer 2022
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
Fontana A, Cursaro I, Carullo G, Gemma S, Butini S, Campiani G
International journal of molecular sciences 2022
Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro
Xie H, Rutz J, Maxeiner S, Grein T, Thomas A, Juengel E, Chun FK, Cinatl J, Haferkamp A, Tsaur I, Blaheta RA
Cancers 2022
Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
Zhang P, Du Y, Bai H, Wang Z, Duan J, Wang X, Zhong J, Wan R, Xu J, He X, Wang D, Fei K, Yu R, Tian J, Wang J
BMC Medicine 2022
BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma
Zhu Q, Gu X, Wei W, Wu Z, Gong F, Dong X
Cancer Medicine 2022

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 7 X users
18 readers on Mendeley
See more details